A Study of SGT-53 in Children With Refractory or Recurrent Solid Tumors
Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the dose limiting toxicities and recommended phase
2 dose of SGT-53 alone and in combination with topotecan and cyclophosphamide in pediatric
patients with recurrent or refractory solid tumors.